J&J's 1st-qtr 2006 earnings up 16.4%, but sales weak

23 April 2006

US health care giant Johnson & Johnson has announced first quarter 2006 sales of $13.0 billion, up a modest 1.2%. Net earnings for the period were $3.3 billion, a 16.4% increase on the year earlier period, which equates to diluted earnings per share of $1.10. The firm added that this includes the $368.0 million it received following the termination of its 2004 agreement to acquire US medical device maker Guidant, which was bettered by Boston Scientific (Marketletter January 30).

Also during the first quarter, the company reported that it incurred $29.0 million in process R&D charges associated with its purchase, through two of its member companies, of Miami, Florida-based Hand Innovations and French firm Future Medical Systems.

1st-qtr pharmaceutical sales down 2.2%

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.